American Pharmaceutical Security Act
- Sponsor
- Sen. Schiff, Adam B. [D-CA]
- Committees
- Finance Committee (primary)
- Last action
- Aug 6, 2026
Bottom line
This bill requires a federal report on strategies to use Medicare and Medicaid payment policies to bolster the domestic supply chain for critical pharmaceutical components and reduce foreign dependency.
What it actually does
This bill mandates that the Administrator of the Centers for Medicare & Medicaid Services (CMS) submit a report to Congress within one year of enactment. The report must include findings and policy recommendations on how CMS's coverage and reimbursement authorities can be utilized to protect U.S. and allied markets for active pharmaceutical ingredients (APIs) and key starting materials (KSMs), thereby reducing dependence on foreign adversaries.
Proponents argue
Supporters argue this bill is a crucial first step in identifying concrete strategies to secure the U.S. pharmaceutical supply chain, which has been exposed as vulnerable during recent global crises. They contend that leveraging CMS's significant purchasing power through coverage and reimbursement policies can incentivize domestic manufacturing and reduce reliance on potentially hostile foreign sources, ensuring access to essential medicines.
Opponents contend
Critics might argue that mandating such a report could lead to recommendations that interfere with free market principles, potentially increasing drug costs for consumers or limiting access to certain medications if domestic production proves more expensive or less efficient. They might also raise concerns about the administrative burden on CMS to produce such a comprehensive report within the specified timeframe.
The bill is very short and straightforward, making it highly accessible for any reader to understand its core intent and provisions quickly.
Section 2(a) and 2(b)
Requirement for CMS Report on Pharmaceutical Supply Chain Security
This section mandates that the Administrator of the Centers for Medicare & Medicaid Services (CMS) submit a report to Congress within one year of the bill's enactment. The report must detail findings and policy recommendations on how CMS can use its existing coverage and reimbursement powers to protect U.S. and allied markets for active pharmaceutical ingredients (APIs) and key starting materials (KSMs), aiming to lessen dependence on foreign adversaries for these critical components. The report may include recommendations for price floor commitments and prioritization of domestically manufactured APIs/KSMs, and must identify data gaps.
Supporters argue
Supporters argue that this report is essential for developing a coherent national strategy to secure the pharmaceutical supply chain, which is vital for public health and national security. They believe that by exploring CMS's role, the government can proactively address vulnerabilities and foster a more resilient domestic manufacturing base for critical medicines.
Critics contend
Critics might contend that while the goal is laudable, focusing solely on CMS's authorities might be too narrow, potentially overlooking broader economic and trade policies that could more effectively address supply chain security. They might also worry that the report's recommendations could lead to protectionist policies that increase costs without guaranteed improvements in supply chain resilience.
Tradeoffs
The bill seeks to balance national security and supply chain resilience with potential impacts on market efficiency and drug costs. The tension lies in whether incentivizing domestic production through coverage and reimbursement policies will lead to higher prices or reduced competition, versus the security benefits of reduced foreign dependency.
Defines "foreign adversaries" by referencing section 791.4 of title 15, Code of Federal Regulations (or any successor regulations).
Section 2(a)
Why it matters:This is standard legislative practice to avoid redundancy and ensure consistency with existing legal definitions.
Case for: Referencing existing regulations ensures legal consistency and avoids creating new, potentially conflicting definitions for "foreign adversaries," streamlining the legislative process.
Case against: A reader unfamiliar with 15 CFR 791.4 would need to consult external documents to fully understand which entities are considered "foreign adversaries" under this bill, potentially obscuring the scope of the bill's intent.
Estimated impact: Clarifies the scope of nations whose pharmaceutical industries would be targeted for reduced dependence.